Modulating the m6A Modified Transcription Factor GATA6 Impacts Epithelial Cytokines in Acute Lung Injury

Ai Jin1, Li Li1, Yan Zhao1

  • 1Department of Animal Science, College of Animal Science and Technology, Northwest A&F University, Xianyang, Shaanxi Province, China.

Insights

Methyltransferase-like 3 (METTL3)-mediated N6-position of adenosine (m6A) modification of GATA-binding factor 6 (GATA6) mRNA inhibits acute lung injury (ALI). This finding reveals a new therapeutic target for lung inflammation.

Area of Science:

  • Molecular Biology
  • Immunology
  • Cell Biology

Background:

  • N6-position of adenosine (m6A) methylation is linked to inflammatory responses.
  • The specific role of m6A modification in airway epithelial cells during acute lung injury (ALI) remains unclear.

Purpose of the Study:

  • To investigate the role and mechanism of m6A modification, specifically involving methyltransferase-like 3 (METTL3), in airway epithelial cells during ALI.

Main Methods:

  • Investigated METTL3 and m6A levels in ALI mouse models and human bronchial epithelial cells (BEAS-2B).
  • Utilized cell coculture systems with peripheral blood monocytes and TNF-α stimulation.
  • Performed gene knockdown and overexpression experiments for METTL3 and GATA6.
  • Employed sequencing and functional analysis to determine the mechanism of METTL3 action on GATA6 mRNA.

Main Results:

  • METTL3 and m6A levels were reduced in ALI lung tissues and in BEAS-2B cells stimulated with TNF-α.
  • METTL3 knockdown exacerbated IL-6 and TNF-α release, while METTL3 overexpression reduced proinflammatory cytokines.
  • METTL3-mediated m6A modification of GATA6 mRNA leads to its degradation, thereby inhibiting inflammation.
  • GATA6 knockdown reversed TNF-α-induced inflammatory cytokine secretion.

Conclusions:

  • METTL3-mediated m6A modification of GATA6 mRNA plays a critical inhibitory role in airway epithelial cell inflammation during ALI.
  • METTL3 acts by promoting GATA6 mRNA degradation.
  • METTL3 represents a potential therapeutic target for ALI and related inflammatory lung diseases.